Amundi Boosts Stake in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Amundi boosted its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 143.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,816 shares of the company’s stock after buying an additional 5,199 shares during the quarter. Amundi’s holdings in Fulgent Genetics were worth $166,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in Fulgent Genetics by 45.5% in the 4th quarter. GAMMA Investing LLC now owns 2,133 shares of the company’s stock valued at $39,000 after acquiring an additional 667 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in Fulgent Genetics by 5.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 35,324 shares of the company’s stock valued at $652,000 after acquiring an additional 1,689 shares during the last quarter. Centiva Capital LP raised its holdings in Fulgent Genetics by 16.5% in the 3rd quarter. Centiva Capital LP now owns 12,538 shares of the company’s stock valued at $272,000 after acquiring an additional 1,774 shares during the last quarter. Point72 DIFC Ltd acquired a new position in Fulgent Genetics in the 3rd quarter valued at $46,000. Finally, TCW Group Inc. raised its holdings in Fulgent Genetics by 2.7% in the 4th quarter. TCW Group Inc. now owns 123,400 shares of the company’s stock valued at $2,279,000 after acquiring an additional 3,300 shares during the last quarter. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Fulgent Genetics Trading Up 1.2 %

Shares of FLGT opened at $17.09 on Friday. The firm has a market capitalization of $526.87 million, a P/E ratio of -3.10 and a beta of 1.54. The stock’s fifty day simple moving average is $16.84 and its 200 day simple moving average is $18.84. Fulgent Genetics, Inc. has a twelve month low of $14.57 and a twelve month high of $25.11.

Analyst Ratings Changes

Several research analysts have weighed in on FLGT shares. StockNews.com upgraded Fulgent Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, March 5th. Piper Sandler cut their price target on Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th.

Insider Buying and Selling

In other news, CFO Paul Kim bought 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average cost of $15.96 per share, with a total value of $1,596,000.00. Following the transaction, the chief financial officer now owns 348,282 shares of the company’s stock, valued at $5,558,580.72. This represents a 40.28 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 31.76% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.